Bank of America Corp DE acquired 561,724 shares of Mirum Pharmaceuticals for approximately $65.8 million. This purchase represents a 0.87% ownership stake in the company.
Analysts maintain a Moderate Buy consensus rating on the stock. The average price target is currently set at $137.31.
The investment follows recent insider activity, including a significant share sale by CEO Christopher Peetz.
Mirum reported a 37.9% year-over-year revenue increase in its latest financial filing. The company’s loss per share was wider than analysts anticipated.